New Findings from DESTINY Breast09 Challenge Treatment Norms
Interim findings from the DESTINY Breast09 trial reveal promising efficacy for trastuzumab deruxtecan, potentially reshaping first-line treatment for patients with HER2 positive metastatic breast cancer. The study compares this innovative…